Chronic Lymphocytic Leukemia: Current Knowledge and Future Advances in Cytogenomic Testing Chronic Lymphocytic Leukemia
Main Article Content
ABSTRACT
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. CLL remains incurable despite improvements in clinical outcomes from the identification of prognostic markers and the introduction of targeted therapies. Recent studies have identified differences in the epigenetic and the regulatory landscape of CLL that may provide molecular targets for future therapies. Optical genome mapping (OGM) is a new method that may improve clinical testing and CLL patient care because it can provide greater sensitivity and resolution of structural variation (SV) that is currently detected by chromosome banding analysis (CBA). The practical issues around diagnosis, molecular cytogenetic prognostic markers, pathobiology, and targeted therapies are discussed with brief reference to OGM.
Downloads
Metrics
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.